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Abstract 
Background: Interleukin 6 (IL6) is pro-inflammatory cytokine associated with decline in ovarian function 
during menopause which is involved in the pathophysiology of postmenopausal bone loss. 
Objective: To investigate validity of salivary IL6 as a biomarker to diagnose osteoporosis in post-menopausal 
women. 
Patients and Methods: This cross sectional study was conducted on 75 postmenopausal women. Bone mineral 
density (BMD) was measured by dual energy x-ray absorptiometry (DXA) to diagnose osteoporosis. Salivary 
IL6 was measured for all postmenopausal women by using Human ELISA kit. 
Results: Of a total 75 individual involved in the study, 25 were healthy postmenopausal women, 25 had 
osteopenia, and 25 had osteoporosis. There was no statistical significant differences between age and body mass 
index in all groups (p>0.05). Mean level of salivary IL6 was significantly different among healthy controls, 
osteopenic group, and osteoporotic group (11.66 ± 4.44 vs 14.51 ± 6.5 vs 23.9 ±5.52 pg/ml; p<0.001) 
respectively. The mean salivary IL-6 was significantly higher in osteoporosis group (23.9 pg/ml) compared to 
control group (11.66 pg/ml). Salivary IL-6 was a valid parameter to predict osteoporosis in postmenopausal 
woman (ROC area=0.91, p<0.001).Salivary IL-6 showed positive strong significant linear correlation with bone 
t- score (r=0.62,     P<0.001). Salivary IL6 at the optimum cut off value ≥19.45 pg/ml has highest accuracy 
(81.3%) to diagnose osteoporosis in postmenopausal women  with sensitivity was 84.%, specificity 80 %, 
positive predictive value (PPV) at pretest probability 50% was 80.8%,  and PPV at pretest probability 90% was 
97.4 %,  and  negative predictive value (NPV) at pretest  probability 10% was 97.8 %. 
Conclusions: Salivary IL6 was a simple, easy, and a valid biomarker to diagnose osteoporosis in 
postmenopausal women with high accuracy. This may indicate a hopeful measure for early diagnosis and 
treatment of osteoporosis. 
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1. Introduction 
Osteoporosis prevalence is consistently increasing due to increased life expectancy worldwide. It is known that 
one of the most common causes of hospitalization among elderly postmenopausal women is hip fractures due to 
osteoporosis [1–3]. Nearly half of all women are expected to suffer an osteoporotic fracture in their lifetime with 
subsequent functional dependent that requires long term nursing care, and increasing in mortality [4]. 
Thus, most relevant studies aimed at developing new measures and treatment modalities to reduce the 
burden of this health problem [5]. In recent years, saliva-based diagnostic tests have increased in popularity 
because of their non-invasive nature. Using saliva rather than serum has benefits: it is non-invasive, easy to 
obtain, painless and there is no need to employ specially trained personal for sample collection [6, 7]. Cytokines, 
the key regulators of the immune responses, are crucially involved in neuroendocrine immune interactions, 
whereas estrogen appears to regulate immune function [8-10]. IL6 is pro-inflammatory cytokines associated with 
the decline in ovarian function in menopause have been shown to act as bone-resorbing cytokines.  The 
alteration in cytokines during menopausal transition is involved in the pathogenesis, development, and 
progression of postmenopausal osteoporosis [11]. This study was carried out to investigate salivary IL6 in 
postmenopausal women with osteoporosis. 
 
2. Patients and Methods 
2.1 Study design 
This cross-sectional study was conducted in Institute of Radiology, Baghdad Medical City from 23rd of 
September 2014 till 10th   of February 2015. Informed consent was taken from all participants in the study and 
ethical approval had been obtained from the Ethics Committee of Department of Oral Diagnosis, College of 
Dentistry, University of Baghdad. 
 
2.2 Sample selection 
Eligible individuals included in the study were postmenopausal women who had experienced at least 12 
consecutive months of amenorrhea. The postmenopausal stage was defined as a stage beginning at the time of 
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the woman final menstrual period [12].Subjects were excluded from the study if they had: diabetes mellitus, 
thyroid and parathyroid disease, autoimmune diseases, history of periodontal therapy within the last 3 months; 
current use of medications such as corticosteroids or any immune suppressive within the previous 3 months, 
chemotherapy, ovarictomy; smokers, alcohol users, fracture and neoplastic diseases 
 
2.3 Clinical, laboratory, and radiological evaluation 
A Questionnaire paper consisted of age, weight, height, and body mass index (BMI) which was measured 
according the equation BMI=weight / height 2,  and duration of menopause. 
About seven ml of unstimulated whole saliva were collected from each postmenopausal woman under 
standardized conditions, following the instruction cited by Tenovuo and Lagerloff [13]. Collection done at the 
morning from ( 9-12 am) the subjects were stopped drinking and eating at least one hour prior to the collection 
and asked to rinse their mouth out well (without drinking the water) to remove any possible debris or 
contaminating materials. Subjects were asked to spit in to the collection cup for up to 10 minutes. After 
collection of unstimulated saliva samples each one was centrifuged at 3000 rpm for 10 minutes, the clear 
supernatant was separated, divided in parts in sterile eppendorffs and stored frozen at 280C deep freeze until 
analysis on each tub a subject name was recorded by water resistance marker [13]. 
For cytokine determination saliva samples were stored at -800C. Salivary IL- 6 was analyzed by using 
Human enzyme-linked immunosorbent assay (ELISA) kit for IL6 (Abcam, USA). 
The diagnosis of the osteoporotic patients was made by rheumatologist according to the results of BMD 
(WHO, 1994) using dual x-ray absorptiometry scan (DXA scan: central DXA type DEXXUM 3). All women 
were divided into three groups according to the results of BMD (WHO, 1994) [14]: Group one: twenty five post 
postmenopausal women with osteoporosis (T score ≤ -2.5), Group two: twenty five post postmenopausal women 
with osteopenia: T score between −1 and −2.5 standard deviations below the mean value of peak bone mass. 
Group three: 25 healthy postmenopausal women (T score ≥ -1.0). 
 
2.4 Statistical analysis 
Statistical software (SPSS version 22, IBM, USA) was used for data analysis. Kolmogorov-Semirnov test was 
done to assess the distribution of continuous variables (Age, BMI, duration of menopause and salivary IL6). The 
statistical significance of differences in mean of a normally distributed variable between 2 groups was assessed 
by independent samples t-test. The statistical significance of differences in mean of a normally distributed 
variable between more than 2 groups was assessed by ANOVA test. When ANOVA model detects a statistically 
significant difference, further exploration for statistical significance of difference in mean between all possible 
paired combinations of study groups was performed using LSD (least significant difference). The statistical 
significance, direction and strength of linear correlation between 2 quantitative variables, one of which being 
non-normally distributed variable was measured by Spearman’s Rho linear correlation coefficient. A  receiver  
operating  characteristic (ROC)  curve  analysis  was  used  to  assess  validity  parameters  and  set  optimum  
cut-off  values  for  salivary IL6 when used to predict a diagnosis of osteoporosis P value less than the 0.05 level 
of significance was considered statistically significant. 
 
3. Results 
A total of 75 postmenopausal women involved in the study, of them 25 were healthy controls, 25 osteopenic 
patients, and 25 were osteoporotic patients. The mean age of patients with osteoporosis was (52.2±5.3) years, 
osteopenia (56.1±4.2) years; and control subjects (55±5.1).There was no statistical significant difference 
between the groups (P= 0.07).The mean duration of menopause was highest in osteoporosis group (9.2±6.3) and 
the lowest was in control group (4.4±2.8) years. The mean duration of menopause was significantly higher in 
osteoporosis group (9.2) years compared to control group (4.4) years   (p<0.001.On the other hand the mean 
duration of menopause was obviously higher in osteopenia group (8.2±4.5) years compared to control group 
(4.4±2.8) years, P= 0.005, but the mean duration of menopause in osteoporosis was not significantly different 
from osteopenic patients. The (mean ±SD) of body mass index (BMI) in osteoporosis patients was 
(30.8±5.7)kg/m², while the (mean ±SD) of BMI in osteopenia patients and in control subjects was (31.4±5.5) 
kg/m² and (33.8±4.9) kg/m² respectively. The difference in mean between studied groups was not statistically 
significant (p= 0.46). 
In table 1: The mean salivary IL-6 was highest in osteoporosis group (23.9 pg/ml ) and  lowest in 
control group (11.66 pg/ml) .The mean salivary IL-6 was significantly higher in osteoporosis group compared to 
control group (23.9 pg/ml vs11.66 pg/ml, p<0.001).The mean salivary IL-6 was obviously higher in osteopenia 
group (14.51 pg/ml) compared to control group (11.66 pg/ml), but the observed difference failed to reach the 
level of statistical significance(P>0.05). The effect of osteoporosis on increasing salivary IL-6 was stronger 
(ROC area=0.95) than that of osteopenia (ROC area=0.64). In addition, salivary IL-6 showed a statistical 
significant difference between the study groups p<0.001) and statistical significant strong positive linear 
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correlation of salivary IL6 with bone t- score (r=0.62, P<0.001).  
Salivary IL-6 was a valid parameter to predict osteoporosis in postmenopausal woman (ROC area=0.91, 
p<0.001) as shown in table 2.  
The best cut-off value providing the best separation between postmenopausal women with osteoporosis 
and those without osteoporosis was salivary IL-6 concentration 19.45 pg/ml which had highest accuracy (81.3%) 
and was associated with a sensitivity of 84 % and specificity of 80 %.  And Testing positive at this optimum cut-
off will establish a diagnosis of osteoporosis with 80.8% confidence in clinical context where the pretest 
probability of having osteoporosis is 50% (equal odds for having osteoporosis versus not having it). However, 
when the clinical context of osteoporosis is of high probability based on clinical suspicion only (pretest 
probability =90%) then it will establish the diagnosis with 97.4% confidence (Table 3). 
 
Table 1: The difference in mean salivary IL-6 between study groups 
Study group 
Healthy 
controls Osteopenia Osteoporosis P 
Salivary IL-6 (pg/ml)    
 
<0.001 
Range (5.85 to 20.5) (6.98 to 31.16) (13.28 to 31.94) 
Mean 11.66 14.51 23.9 
SD 4.44 6.5 5.52 
SE 0.888 1.3 1.105 
N 25 25 25 
P (LSD) for the difference in mean between: 
 Osteopenia x Healthy controls = 0.07[NS] 
 Osteoporosis x Healthy controls = <0.001 
 Osteoporosis x Osteopenia = 0.001 
 Effect size (ROC area P value) 
 Osteopenia X Healthy (ROC=0.65     P=0.06[NS]) 
 Osteoporosis X Healthy (ROC=0.95   P<0.001) 
 Osteoporosis X Osteopenia (ROC=0.86 P<0.001) 
 Linear correlation with t-score: 
      r=0.62 
     P<0.001 
 
Table 2: ROC area for salivary IL6 when used as test to predict osteoporosis among postmenopausal women 
Predicting Osteoporosis ROC P 
 
Salivary IL6 
 
0.91 
 
<0.001 
 
   ROC, receiver operating characteristics 
 
Table 3: Validity parameters of salivary IL6 level in predicting osteoporosis 
  
PPV at pretest 
probability =  
NPV at pretest 
probability = 
10% Positive if ≥ cut-off value  Sensitivity Specificity Accuracy 50% 90% 
Salivary IL6 level,  pg/ml 
13.15 (Highest sensitivity) 100.0 68.0 78.7 75.8 96.6 100.0 
19.45 (optimum cutoff value) 84.0 80.0 81.3 80.8 97.4 97.8 
31.33 Highest specificity) 8.0 100.0 69.3 100.0 100.0 90.7 
   PPV, positive predictive value; NPV, negative predictive value    
 
4. Discussion 
Postmenopausal osteoporosis is a very common metabolic disease that has no clinical features except when there 
is a fracture, so early diagnosis and treatment is very important. This study investigated salivary IL6 in 
postmenopausal women with osteoporosis and found that mean salivary IL-6 was significantly higher in 
osteoporosis group compared to control group. In addition. Salivary IL6 was a valid biomarker to diagnose 
osteoporosis in postmenopausal women with high accuracy. 
The impact of IL6 in postmenopausal women may be related to the fact that IL6 is a pro-inflammatory 
cytokine and interacts in complex ways with the cells involved in bone remodeling. It may indirectly promote 
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osteoclastogenesis by increasing the release of RANK-L by osteoblasts, and it diminishes the proliferation of 
osteoblasts at late differentiation stages and subsequently led to osteoporosis. [15]. 
Interestingly, the current study reported that salivary IL6 was an excellent predictor for osteoporosis in 
postmenopausal woman with strong effect size (ROC area=0.91, <0.001). This is clinically relevant because it 
may help us to differentiate healthy women from post-menopausal women with osteoporosis and suggest early 
diagnosis and appropriate targeted treatment. 
In addition, at optimum cut off value≥ 19.45 pg/ml, we got the highest accuracy (81.3%), with 
sensitivity 84%, specificity 80%,. And a positive result of salivary IL6 test established a diagnosis of 
postmenopausal women with osteoporosis with 80.8 % confidence in a clinical setting in which the odds of 
having the osteoporosis were equal between healthy and postmenopausal osteoporotic women, while in a clinical 
setting in which osteoporosis was highly suspected (90% pretest probability, based on clinical or other criteria 
apart from the test under question, The confidence was 97.4 %. A negative salivary IL6 result excluded a 
possible diagnosis of osteoporosis in postmenopausal women with 97.8 % confidence in a clinical setting in 
which the differential diagnosis of osteoporosis was considered to be of very low probability (10% pretest 
probability).This may suggest a valid easy test with high accuracy and confidence for early assessment  and 
screening of  post-menopausal women for osteoporosis that subsequently rapid diagnosis and treatment to 
prevent complications of osteoporotic fractures which has high morbidity and mortality. 
Several studies have reported that proinflammatory cytokine IL6 have been implicated in the regulation 
of bone cells and play a critical role in bone remodeling. It acts both directly and indirectly to increase bone 
resorption, and/or inhibit bone formation.  Al-Daghri et al [16] proved that the IL6 accelerate the bone loss in 
postmenopausal women. Zupan et al [17] demonstrated a higher expression of interleukin (IL)-6 in 
postmenopausal woman with osteoporosis. Desai et al [18] reported that IL6 correlates negatively with estrogens 
and BMD. Other studies demonstrated that IL6 negatively correlated with Bone mineral density and increased 
circulating levels of IL6 with high bone turnover and resorption in postmenopausal women [19, 20] 
The limitation of this study was low number of patients that can be solved by a larger and longer 
prospective study. However the strength of the current study included strong inclusion and exclusion criteria in 
addition to being the first cross sectional study in Iraq that assessed salivary IL6 in postmenopausal women with 
osteoporosis. 
 
5. Conclusion 
Salivary IL6 was a simple, easy, and a valid biomarker to diagnose osteoporosis in postmenopausal women with 
high accuracy, sensitivity and specificity. This may indicate a hopeful measure for early diagnosis and targeted 
treatment of postmenopausal women with osteoporosis. 
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